Trial Profile
A Single-dose, Nested-randomized, Double-blind, Double-dummy, Placebo- and Active-controlled Crossover Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2021
Price :
$35
*
At a glance
- Drugs Cebranopadol (Primary) ; Hydromorphone
- Indications Back pain; Musculoskeletal pain; Opioid-related disorders
- Focus Adverse reactions
- Sponsors Grunenthal; Tris Pharma
- 05 Dec 2018 New trial record